Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

B. Qiu; K.C. Cai; C. Chen; J. Chen; K.N. Chen; Q.X. Chen; C. Cheng; T.Y. Dai; J.Q. Fan; Z.H. Fan; J. Hu; W.D. Hu; Y.C. Huang; G.N. Jiang; J. Jiang; T. Jiang; W.J. Jiao; H.C. Li; Q. Li; Y.D. Liao; H.X. Liu; J.F. Liu; L.X. Liu; Y. Liu; H. Long; Q.Q. Luo; H.T. Ma; N.Q. Mao; X.J. Pan; F.W. Tan; L.J. Tan; H. Tian; D. Wang; W.X. Wang; L. Wei; N. Wu; Q.C. Wu; J.Q. Xiang; S.D. Xu; L. Yang; H. Zhang; L.J. Zhang; P. Zhang; Y. Zhang; Z.F. Zhang; K.S. Zhu; Y.M. Zhu; S.W. Um; I.J. Oh; Y. Tomita; D. De Ruysscher; B.L. Vanneste; Shugeng Gao

doi:10.21037/tlcr-21-634

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

B. Qiu, K.C. Cai, C. Chen, J. Chen, K.N. Chen, Q.X. Chen, C. Cheng, T.Y. Dai, J.Q. Fan, Z.H. Fan, J. Hu, W.D. Hu, Y.C. Huang, G.N. Jiang, J. Jiang, T. Jiang, W.J. Jiao, H.C. Li, Q. Li, Y.D. LiaoH.X. Liu, J.F. Liu, L.X. Liu, Y. Liu, H. Long, Q.Q. Luo, H.T. Ma, N.Q. Mao, X.J. Pan, F.W. Tan, L.J. Tan, H. Tian, D. Wang, W.X. Wang, L. Wei, N. Wu, Q.C. Wu, J.Q. Xiang, S.D. Xu, L. Yang, H. Zhang, L.J. Zhang, P. Zhang, Y. Zhang, Z.F. Zhang, K.S. Zhu, Y.M. Zhu, S.W. Um, I.J. Oh, Y. Tomita, D. De Ruysscher, B.L. Vanneste, Shugeng Gao^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary

Original language	English
Pages (from-to)	3713-3736
Number of pages	24
Journal	Translational Lung Cancer Research
Volume	10
Issue number	9
DOIs	https://doi.org/10.21037/tlcr-21-634
Publication status	Published - 1 Sept 2021

Keywords

STAGING PROJECT PROPOSALS
FORTHCOMING 8TH EDITION
NEOADJUVANT CHEMOTHERAPY
SINGLE-ARM
PREOPERATIVE CHEMOTHERAPY
HISTOPATHOLOGIC RESPONSE
TNM CLASSIFICATION
OPEN-LABEL
MULTICENTER
NSCLC

Access to Document

10.21037/tlcr-21-634Licence: CC BY-NC-ND

Cite this

Qiu, B., Cai, K. C., Chen, C., Chen, J., Chen, K. N., Chen, Q. X., Cheng, C., Dai, T. Y., Fan, J. Q., Fan, Z. H., Hu, J., Hu, W. D., Huang, Y. C., Jiang, G. N., Jiang, J., Jiang, T., Jiao, W. J., Li, H. C., Li, Q., ... Gao, S. (2021). Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 10(9), 3713-3736. https://doi.org/10.21037/tlcr-21-634

@article{dac5e5fd0d754c518beba6defe4a8b65,

title = "Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer",

abstract = "The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary",

keywords = "STAGING PROJECT PROPOSALS, FORTHCOMING 8TH EDITION, NEOADJUVANT CHEMOTHERAPY, SINGLE-ARM, PREOPERATIVE CHEMOTHERAPY, HISTOPATHOLOGIC RESPONSE, TNM CLASSIFICATION, OPEN-LABEL, MULTICENTER, NSCLC",

author = "B. Qiu and K.C. Cai and C. Chen and J. Chen and K.N. Chen and Q.X. Chen and C. Cheng and T.Y. Dai and J.Q. Fan and Z.H. Fan and J. Hu and W.D. Hu and Y.C. Huang and G.N. Jiang and J. Jiang and T. Jiang and W.J. Jiao and H.C. Li and Q. Li and Y.D. Liao and H.X. Liu and J.F. Liu and L.X. Liu and Y. Liu and H. Long and Q.Q. Luo and H.T. Ma and N.Q. Mao and X.J. Pan and F.W. Tan and L.J. Tan and H. Tian and D. Wang and W.X. Wang and L. Wei and N. Wu and Q.C. Wu and J.Q. Xiang and S.D. Xu and L. Yang and H. Zhang and L.J. Zhang and P. Zhang and Y. Zhang and Z.F. Zhang and K.S. Zhu and Y.M. Zhu and S.W. Um and I.J. Oh and Y. Tomita and {De Ruysscher}, D. and B.L. Vanneste and Shugeng Gao",

year = "2021",

month = sep,

day = "1",

doi = "10.21037/tlcr-21-634",

language = "English",

volume = "10",

pages = "3713--3736",

journal = "Translational Lung Cancer Research",

issn = "2226-4477",

publisher = "AME Publishing Company",

number = "9",

}

Qiu, B, Cai, KC, Chen, C, Chen, J, Chen, KN, Chen, QX, Cheng, C, Dai, TY, Fan, JQ, Fan, ZH, Hu, J, Hu, WD, Huang, YC, Jiang, GN, Jiang, J, Jiang, T, Jiao, WJ, Li, HC, Li, Q, Liao, YD, Liu, HX, Liu, JF, Liu, LX, Liu, Y, Long, H, Luo, QQ, Ma, HT, Mao, NQ, Pan, XJ, Tan, FW, Tan, LJ, Tian, H, Wang, D, Wang, WX, Wei, L, Wu, N, Wu, QC, Xiang, JQ, Xu, SD, Yang, L, Zhang, H, Zhang, LJ, Zhang, P, Zhang, Y, Zhang, ZF, Zhu, KS, Zhu, YM, Um, SW, Oh, IJ, Tomita, Y, De Ruysscher, D, Vanneste, BL & Gao, S 2021, 'Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer', Translational Lung Cancer Research, vol. 10, no. 9, pp. 3713-3736. https://doi.org/10.21037/tlcr-21-634

TY - JOUR

T1 - Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

AU - Qiu, B.

AU - Cai, K.C.

AU - Chen, C.

AU - Chen, J.

AU - Chen, K.N.

AU - Chen, Q.X.

AU - Cheng, C.

AU - Dai, T.Y.

AU - Fan, J.Q.

AU - Fan, Z.H.

AU - Hu, J.

AU - Hu, W.D.

AU - Huang, Y.C.

AU - Jiang, G.N.

AU - Jiang, J.

AU - Jiang, T.

AU - Jiao, W.J.

AU - Li, H.C.

AU - Li, Q.

AU - Liao, Y.D.

AU - Liu, H.X.

AU - Liu, J.F.

AU - Liu, L.X.

AU - Liu, Y.

AU - Long, H.

AU - Luo, Q.Q.

AU - Ma, H.T.

AU - Mao, N.Q.

AU - Pan, X.J.

AU - Tan, F.W.

AU - Tan, L.J.

AU - Tian, H.

AU - Wang, D.

AU - Wang, W.X.

AU - Wei, L.

AU - Wu, N.

AU - Wu, Q.C.

AU - Xiang, J.Q.

AU - Xu, S.D.

AU - Yang, L.

AU - Zhang, H.

AU - Zhang, L.J.

AU - Zhang, P.

AU - Zhang, Y.

AU - Zhang, Z.F.

AU - Zhu, K.S.

AU - Zhu, Y.M.

AU - Um, S.W.

AU - Oh, I.J.

AU - Tomita, Y.

AU - De Ruysscher, D.

AU - Vanneste, B.L.

AU - Gao, Shugeng

PY - 2021/9/1

Y1 - 2021/9/1

N2 - The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary

AB - The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary

KW - STAGING PROJECT PROPOSALS

KW - FORTHCOMING 8TH EDITION

KW - NEOADJUVANT CHEMOTHERAPY

KW - SINGLE-ARM

KW - PREOPERATIVE CHEMOTHERAPY

KW - HISTOPATHOLOGIC RESPONSE

KW - TNM CLASSIFICATION

KW - OPEN-LABEL

KW - MULTICENTER

KW - NSCLC

U2 - 10.21037/tlcr-21-634

DO - 10.21037/tlcr-21-634

M3 - Article

C2 - 34733623

SN - 2226-4477

VL - 10

SP - 3713

EP - 3736

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 9

ER -